Zelira Therapeutics Limited (ZLDAF)
USD 0.35
(0.0%)
USD 0.35
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 10.28 Thousand AUD | -99.75% |
| 2023 | 4.19 Million AUD | -70.54% |
| 2022 | 14.24 Million AUD | 39.74% |
| 2021 | 10.19 Million AUD | 28.46% |
| 2020 | 7.93 Million AUD | 87.26% |
| 2019 | 4.23 Million AUD | 49.86% |
| 2018 | 2.82 Million AUD | -55.28% |
| 2017 | 6.32 Million AUD | 621.62% |
| 2016 | 876.42 Thousand AUD | 106.79% |
| 2015 | 423.82 Thousand AUD | 43.58% |
| 2014 | 295.17 Thousand AUD | -8.35% |
| 2013 | 322.06 Thousand AUD | -48.93% |
| 2012 | 630.62 Thousand AUD | 36.18% |
| 2011 | 463.08 Thousand AUD | -59.74% |
| 2010 | 1.15 Million AUD | -37.98% |
| 2009 | 1.85 Million AUD | 280.06% |
| 2008 | 487.99 Thousand AUD | -98.95% |
| 2007 | 46.55 Million AUD | 3352.39% |
| 2006 | 1.34 Million AUD | 56.67% |
| 2005 | 860.64 Thousand AUD | -17.05% |
| 2004 | 1.03 Million AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 17.02 Million AUD | 523.29% |
| 2024 Q2 | 2.23 Million AUD | -86.88% |
| 2024 FY | 4.78 Million AUD | 14.01% |
| 2024 Q3 | 1.16 Million AUD | -47.78% |
| 2024 Q4 | 1.16 Million AUD | 0.0% |
| 2023 Q2 | 1.46 Million AUD | -5.21% |
| 2023 Q1 | 1.54 Million AUD | -62.0% |
| 2023 FY | 4.19 Million AUD | -70.54% |
| 2023 Q3 | 1.26 Million AUD | -13.76% |
| 2023 Q4 | 2.73 Million AUD | 115.99% |
| 2022 FY | 14.24 Million AUD | 39.74% |
| 2022 Q1 | 2.83 Million AUD | -39.72% |
| 2022 Q2 | 3.62 Million AUD | 27.8% |
| 2022 Q3 | 3.64 Million AUD | 0.47% |
| 2022 Q4 | 4.06 Million AUD | 11.62% |
| 2021 Q1 | 1.83 Million AUD | -56.65% |
| 2021 FY | 10.19 Million AUD | 28.46% |
| 2021 Q3 | 2.63 Million AUD | -46.16% |
| 2021 Q4 | 4.71 Million AUD | 78.5% |
| 2021 Q2 | 4.9 Million AUD | 167.59% |
| 2020 Q3 | 2.21 Million AUD | -33.74% |
| 2020 FY | 7.93 Million AUD | 87.26% |
| 2020 Q1 | 1.29 Million AUD | -44.25% |
| 2020 Q2 | 3.33 Million AUD | 157.89% |
| 2020 Q4 | 4.22 Million AUD | 91.09% |
| 2019 FY | 4.23 Million AUD | 49.86% |
| 2019 Q1 | 1.05 Million AUD | 38.05% |
| 2019 Q2 | 1.05 Million AUD | 0.0% |
| 2019 Q3 | 1.15 Million AUD | 9.73% |
| 2019 Q4 | 2.32 Million AUD | 100.45% |
| 2018 Q4 | 764.47 Thousand AUD | 0.0% |
| 2018 Q3 | 764.47 Thousand AUD | 134.08% |
| 2018 Q2 | 326.58 Thousand AUD | -0.0% |
| 2018 Q1 | 326.58 Thousand AUD | -48.44% |
| 2018 FY | 2.82 Million AUD | -55.28% |
| 2017 Q1 | 2.52 Million AUD | 0.0% |
| 2017 FY | 6.32 Million AUD | 621.62% |
| 2017 Q4 | 633.39 Thousand AUD | 0.0% |
| 2017 Q3 | 633.39 Thousand AUD | -74.96% |
| 2017 Q2 | 2.52 Million AUD | 0.0% |
| 2016 FY | 876.42 Thousand AUD | 106.79% |
| 2015 FY | 423.82 Thousand AUD | 43.58% |
| 2014 FY | 295.17 Thousand AUD | -8.35% |
| 2013 FY | 322.06 Thousand AUD | -48.93% |
| 2012 FY | 630.62 Thousand AUD | 36.18% |
| 2011 FY | 463.08 Thousand AUD | -59.74% |
| 2010 FY | 1.15 Million AUD | -37.98% |
| 2009 FY | 1.85 Million AUD | 280.06% |
| 2008 FY | 487.99 Thousand AUD | -98.95% |
| 2007 FY | 46.55 Million AUD | 3352.39% |
| 2006 FY | 1.34 Million AUD | 56.67% |
| 2005 FY | 860.64 Thousand AUD | -17.05% |
| 2004 FY | 1.03 Million AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 99.305% |
| CSL Limited | 3.44 Billion USD | 100.0% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.988% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 99.791% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | 96.071% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 99.965% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 99.972% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 99.315% |
| Mesoblast Limited | 5.9 Million USD | 99.826% |
| Marizyme, Inc. | 19.23 Million USD | 99.947% |
| Genus plc | 147.7 Million USD | 99.993% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 99.883% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 99.233% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 99.877% |
| ContraFect Corporation | 56.88 Million USD | 99.982% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 99.767% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | 37.7 Million USD | 99.973% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 99.631% |
| MultiCell Technologies, Inc. | 567.42 USD | -1712.414% |
| Accustem Sciences Inc. | 3.74 Million USD | 99.725% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.988% |
| EV Biologics, Inc. | 531.96 Thousand USD | 98.067% |
| Q BioMed Inc. | 3.43 Million USD | 99.701% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 99.958% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 99.609% |
| Biomind Labs Inc. | 994.18 Thousand USD | 98.966% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 99.847% |
| Skye Bioscience, Inc. | 13.54 Million USD | 99.924% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.988% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 141.136% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 99.796% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 99.647% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 99.936% |
| Neon Bloom, Inc. | 389.56 Thousand USD | 97.36% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 99.995% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 99.498% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 99.44% |
| GB Sciences, Inc. | 1.42 Million USD | 99.276% |
| Alpha Cognition Inc. | 9.7 Million USD | 99.894% |
| argenx SE | 1.53 Billion USD | 99.999% |
| HST Global, Inc. | 140.9 Thousand USD | 92.702% |
| Halberd Corporation | 74.84 Thousand USD | 86.259% |
| Enzolytics Inc. | 2.17 Million USD | 99.528% |
| Resverlogix Corp. | 12.71 Million USD | 99.919% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 99.718% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 99.982% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.99% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 99.015% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 99.416% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 99.572% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 99.448% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 99.349% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 99.698% |
| AVAX Technologies, Inc. | 7.31 Million USD | 99.859% |
| ONE Bio Corp. | 6.44 Million USD | 99.84% |
| Zenith Capital Corp. | 8.94 Million USD | 99.885% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.999% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | 40.968% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 99.581% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | 94.004% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 99.465% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 99.086% |
| Agentix Corp. | 1.37 Million USD | 99.25% |
| Adynxx, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 2.41 Million USD | 99.573% |
| Helix BioMedix, Inc. | 1.97 Million USD | 99.479% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 99.905% |
| BioStem Technologies, Inc. | 22.97 Million USD | 99.955% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | 94.333% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | 99.23% |
| LadRx Corporation | 3.81 Million USD | 99.73% |
| Cell Source, Inc. | 4.32 Million USD | 99.762% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 97.525% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 98.886% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 98.886% |
| NovAccess Global Inc. | 2.46 Million USD | 99.583% |
| Affymax, Inc. | 39.38 Million USD | 99.974% |
| Itoco Inc. | 919.14 Thousand USD | 98.881% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 99.757% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 99.081% |
| CytoDyn Inc. | 18.05 Million USD | 99.943% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | 59.14% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | 95.327% |
| Qrons Inc. | 643.67 Thousand USD | 98.402% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 99.276% |
| SYBLEU INC | 160.87 Thousand USD | 93.607% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | 99.539% |
| Rebus Holdings, Inc. | 664 Thousand USD | 98.451% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 99.434% |
| Mobile Lads Corp. | 554.54 Thousand USD | 98.146% |
| International Stem Cell Corporation | 5.27 Million USD | 99.805% |
| Bioxytran, Inc. | 3.82 Million USD | 99.731% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | 80.464% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | 49.447% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 99.972% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 99.364% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 98.602% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 99.669% |
| Neutra Corp. | 243.82 Thousand USD | 95.782% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 99.941% |
| PureTech Health plc | 144.59 Million USD | 99.993% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 99.95% |
| IXICO plc | 4.7 Million USD | 99.782% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 99.883% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.991% |
| CSL Limited | 3.89 Billion USD | 100.0% |
| Cellectis S.A. | 97.32 Million USD | 99.989% |